Pharmazz Archives - Clearspan Strategic

Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke

by michael | Jul 30, 2020 | Pharmazz, Press Releases

Abstract The development of effective drugs for stroke is urgently required as it is the 2nd largest killer in the world and its incidence is likely to increase in the future. We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to treat...

Lyfaquin®, a first-in-class resuscitative agent for patients with excessive blood loss, to be launched in India

by michael | Jul 22, 2020 | Pharmazz, Press Releases

WILLOWBROOK, Ill., July 20, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced that it has successfully received marketing...

Marketing authorization received for Lyfaquin™ (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency

by michael | May 14, 2020 | Pharmazz, Press Releases

WILLOWBROOK, Ill., May 14, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it has received marketing authorization of...

Sovateltide significantly (p=0.0157) improved clinical outcome (modified Rankin Scale) in patients with acute cerebral ischemic stroke when compared to standard of care

by michael | Apr 27, 2020 | Pharmazz, Press Releases

WILLOWBROOK, Ill., April 27, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that sovateltide, an endothelin-B receptor...

Drugs in the Pipeline – Investigational Therapies for COVID-19

by michael | Apr 13, 2020 | News Articles, Pharmazz

Willowbrook, IL (13 April, 2020) /EMPR.com – Centhaquine: An investigational resuscitative agent that is expected to provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome, reduce multiple...

Centhaquine can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, acute respiratory distress syndrome (ARDS), multiple organ dysfunction score (MODS) and mortality in coronavirus disease 2019 (COVID-19) patients

by michael | Apr 9, 2020 | Pharmazz, Press Releases

WILLOWBROOK, Ill., April 9, 2020 /PRNewswire/ — Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of...